FOLD (Amicus Therapeutics Inc) רווח למניה בארבעת הרבעונים האחרונים

Amicus Therapeutics (FOLD) relies on lifelong demand from patients with rare metabolic disorders, creating a stable cash flow. The company is implementing green chemistry to minimize toxic emissions. The current YoY EPS shift over the last 12 months demonstrates earnings per share dynamics, where 51.80 reflects the latest value of the metric. Uninterrupted supplies to clinics are guaranteed by the full utilization of automated production capacities.

The specific positioning of Amicus Therapeutics (FOLD) within the orphan drug segment, characterized by colossal R&D expenditures, makes the annual percentage change in earnings per share (TTM) a key indicator of how effectively the company capitalizes on innovation. This metric calculates the net income growth rate over the last 12 months, allowing investors to assess business resilience against stringent FDA requirements and monetary pressure through the dynamics of per-share returns.